US pharma giant Eli Lilly and Company (Lilly) will build a new pharma manufacturing plant in North Carolina with an investment of more than $470 million for producing injectable products and delivery devices.

The new Lilly pharma manufacturing facility will be built in Research Triangle Park, and will generate over 460 new jobs in Durham. It will be the eight pharma manufacturing plant in the US for Lilly with the remaining seven located across Indiana, New Jersey, and Puerto Rico.

David A. Ricks – chairman and CEO of Lilly, commenting on the new pharma manufacturing plant in North Carolina, said: “This next-generation manufacturing facility will allow us to expand our capacity to make the Lilly medicines that are helping people with serious illnesses today, and help us prepare for new medicines coming from our robust pipeline in the future.

“In the past two years, we have invested billions of capital in new U.S.-based manufacturing because the 2017 tax reform rebalanced the playing field in favor of the American worker. We’re excited to be bringing more of these high-skill, high-wage advanced manufacturing jobs to North Carolina.”

Earlier this month, Lilly signed a deal worth about $1.1 billion to acquire California-based dermatology drug company Dermira. Read more about Lilly acquisition of Dermira here.

  David A. Ricks, Durham, Eli Lilly and Company, North Carolina, Research Triangle Park, USA